Factors influencing survival in sphingosine phosphate lyase insufficiency syndrome: a retrospective cross-sectional natural history study of 76 patients
Nancy Keller,Julian Midgley,Ehtesham Khalid,Harry Lesmana,Georgie Mathew,Christine Mincham,Norbert Teig,Zubair Khan,Indu Khosla,Sam Mehr,Tulay Guran,Kathrin Buder,Hong Xu,Khalid Alhasan,Gonul Buyukyilmaz,Nicole Weaver,Julie D. Saba
DOI: https://doi.org/10.1186/s13023-024-03311-w
2024-09-29
Orphanet Journal of Rare Diseases
Abstract:Sphingosine-1-phosphate lyase insufficiency syndrome (SPLIS) is a recently recognized inborn error of metabolism associated with steroid-resistant nephrotic syndrome as well as adrenal insufficiency and immunological, neurological, and skin manifestations. SPLIS is caused by inactivating mutations in SGPL1 , encoding the pyridoxal 5'phosphate-dependent enzyme sphingosine-1-phosphate lyase, which catalyzes the final step of sphingolipid metabolism. Some SPLIS patients have undergone kidney transplantation, and others have been treated with vitamin B6 supplementation. In addition, targeted therapies including gene therapy are in preclinical development. In anticipation of clinical trials, it will be essential to characterize the full spectrum and natural history of SPLIS. We performed a retrospective analysis of 76 patients in whom the diagnosis of SPLIS was established in a proband with at least one suggestive finding and biallelic SGPL1 variants identified by molecular genetic testing. The main objective of the study was to identify factors influencing survival in SPLIS subjects.
genetics & heredity,medicine, research & experimental